1-20 of 32 results for subject:Screening
Librarians' tools
- Search time
- 0.264 seconds
- Solr query time
- 0.006 seconds
- Search query
- subject:Screening
- We searched for
- subject_t:Screening OR subject_ses:92923
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
Motion lapsed. Motion made and Question proposed, that this House do now adjourn. Agreed to on question.
Motion lapsed. Motion made and Question proposed, that this House do now adjourn. Agreed to on question.
To ask the Secretary of State for Health and Social Care, with reference to the Competition and Markets Authority report entitled, CMA Rapid Review of PCR testing for travel, published in August 2021, on what date his Department responded to that Report's recommendations; and if he will make a statement.
To ask the Secretary of State for Health and Social Care, with reference to the Competition and Markets Authority report entitled, CMA Rapid Review of PCR testing for travel, published in August 2021, on what date his Department responded to that Report's recommendations; and if he will make a statement.
Due to the evolving nature of this policy, the Department did not issue a written response to the Competitions and Markets Authority’s (CMA) report. However, officials met with the CMA on 27 September 2021 to discuss the Department’s response to the CMA’s recommendations and the proposed changes to international travel testing from polymerase chain reaction testing to lateral flow device testing (LFD). On 23 December 2021, officials met with the CMA in light of the transition to LFD testing and the emerging Omicron variant. A further meeting was held in spring 2022.
To ask the Secretary of State for Health and Social Care, what recent assessment the Government has made of the potential effectiveness of creating a market for covid-19 travel testing in helping to ensure a domestic testing capacity.
To ask the Secretary of State for Health and Social Care, what recent assessment the Government has made of the potential effectiveness of creating a market for covid-19 travel testing in helping to ensure a domestic testing capacity.
No specific assessment has been made. Due to the separate domestic and international travel markets, testing in the international travel market would not affect domestic testing capacity.
Agreed to on question.
Agreed to on question.
To ask the Secretary of State for Health and Social Care, what the (a) number and (b) proportion is of people who received PCR test results within (i) 24 hours, (ii) 48 hours, (iii) 72 hours and (iv) 96 hours or more.
To ask the Secretary of State for Health and Social Care, what the (a) number and (b) proportion is of people who received PCR test results within (i) 24 hours, (ii) 48 hours, (iii) 72 hours and (iv) 96 hours or more.
This information is not held in the format requested and could only be obtained at disproportionate cost.
To ask the Secretary of State for Health and Social Care, what plans the Government has to improve the transparency of the Coronavirus Test Device Approval process.
To ask the Secretary of State for Health and Social Care, what plans the Government has to improve the transparency of the Coronavirus Test Device Approval process.
The Government is satisfied with the level of transparency throughout the Coronavirus Test Device Approval process.
To ask the Secretary of State for Health and Social Care, with reference to Ministerial Statement HC WS324 made on 18 October 2021, whether his Department has plans for the continued supply and usage of tests on the Coronavirus Test Device Approvals (CTDA) exempt list after the 28 February 2022...
To ask the Secretary of State for Health and Social Care, with reference to Ministerial Statement HC WS324 made on 18 October 2021, whether his Department has plans for the continued supply and usage of tests on the Coronavirus Test Device Approvals (CTDA) exempt list after the 28 February 2022...
There was no requirement for Coronavirus Test Device Approvals (CDTA) reviews to be completed by 28 February 2022. This date refers to a temporary protocol which applied from 1 November 2021 to 28 February 2022, which allowed tests to stay on the market pending their CTDA outcome.
A new protocol containing two lists took effect from 1 March 2022, one for three months for certain devices until 31 May 2022 and one for six months until 31 August 2022, which is available at the following link:
The new protocol allows the continued supply and procurement of those tests, whilst their CTDA application is being considered.
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 15 February 2022 to Question 119864, what the evidential basis is for the statement that (a) approval of covid-19 tests for private use falls under the Coronavirus Test Devices Approvals regulation (CTDA) and...
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 15 February 2022 to Question 119864, what the evidential basis is for the statement that (a) approval of covid-19 tests for private use falls under the Coronavirus Test Devices Approvals regulation (CTDA) and...
The Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (CTDA) provides a regulatory framework for manufacturers and their representatives seeking to sell COVID-19 tests in-scope of the legislation on the private market or supply tests to private sector testing services in the United Kingdom. It establishes standards to protect consumers and enable high quality tests to enter the market, regardless of the country of origin.
A test must either be approved under the CTDA or be included in a protocol that lists tests that are allowed to remain on the market while their CTDA application is being processed. Tests on the protocol list have received a form of verification, evaluation or validation elsewhere in the public sector, therefore their performance expected to be sufficient to protect public health. The protocol is a temporary measure and long-term access to the UK market is achieved only via CTDA approval.
To ask the Secretary of State for Health and Social Care, what the (a) number and (b) proportion of (i) PPE, (ii) lateral flow tests, (iii) PCR tests and (iv) other covid-19 testing equipment are that have been manufactured by UK based companies.
To ask the Secretary of State for Health and Social Care, what the (a) number and (b) proportion of (i) PPE, (ii) lateral flow tests, (iii) PCR tests and (iv) other covid-19 testing equipment are that have been manufactured by UK based companies.
The Government has ordered 3.9 billion items of personal protective equipment (PPE) from United Kingdom manufacturers. This represents 10.7% of all PPE ordered since the start of the pandemic. We are unable to provide the information requested for lateral flow device and polymerase chain reaction tests and other COVID-19 testing equipment as this information is commercially sensitive.
To ask the Secretary of State for Health and Social Care, if he will publish the (a) details of applications submitted to the Coronavirus Test Device Approval process, (b) dates on which each application was submitted, (c) date on which the applicant company was informed of a decision and (d)...
To ask the Secretary of State for Health and Social Care, if he will publish the (a) details of applications submitted to the Coronavirus Test Device Approval process, (b) dates on which each application was submitted, (c) date on which the applicant company was informed of a decision and (d)...
We are unable to provide the information requested as it is commercially sensitive. The Department publishes details of approved tests including the date of the decision, on GOV.UK at the following link:
https://www.gov.uk/government/publications/covid-19-test-validation-approved-products
If an application is unsuccessful, the applicant can request that we reconsider the decision. Officials continue to work with applicants through this process and guidance is available at the following link:
https://www.gov.uk/guidance/covid-19-test-approval-how-to-apply
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the current delays facing UK Coronavirus Test Device Approval (CTDA) assessments; and what plans his Department has to expedite the backlog before the February 2022 review deadline.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the current delays facing UK Coronavirus Test Device Approval (CTDA) assessments; and what plans his Department has to expedite the backlog before the February 2022 review deadline.
The backlog of tests in the Coronavirus Test Device Approval (CTDA) process was due to insufficient evidence submitted by applicants. We have since worked with applicants on the additional information required and permitted further time to submit this evidence. On 7 February 2022, we updated the online guidance for applicants to provide greater clarity on acceptance criteria for the range of viral loads within samples. The majority of applications are now meeting these standards and the rate of approvals is increasing.
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 15 February 2022 to Question 119864, how many of the 25 per cent of approved devices from UK manufacturers, have a (a) CE marking; and (b) UKCA mark; and how many of those...
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 15 February 2022 to Question 119864, how many of the 25 per cent of approved devices from UK manufacturers, have a (a) CE marking; and (b) UKCA mark; and how many of those...
A valid CE or UKCA marking is required to attain Coronavirus Test Device Approvals (CTDA) approval. All approved devices from United Kingdom manufacturers have a CE marking. All applications for CTDA approval must be made from a place of business registered in the UK. As of 25 February 2022, 14 out of 31 applications approved were from manufacturers established in the UK. All were made from a place of business registered in the UK.
What his latest estimate is of the (a) number and (b) value of contracts for the supply of PPE and covid-19 testing equipment to the NHS which were processed through the High Priority Lane.
What his latest estimate is of the (a) number and (b) value of contracts for the supply of PPE and covid-19 testing equipment to the NHS which were processed through the High Priority Lane.
Mr Speaker, with your permission, as this is a very detailed question, I would like to give a detailed answer.
The PPE high priority lane was established as one way of efficiently triaging and assessing the thousands of offers of support for PPE early in the pandemic. One hundred and fifteen contracts were awarded to 51 suppliers identified through this route and the total value of those contracts was £3.8 billion. Between May 2020 and March 2021, 50 suppliers had priority referrals for covid testing support and were awarded 128 contracts with a total value of £6 billion. All contracts awarded, no matter the route, were rigorously evaluated to ensure
that the products that were progressed met the required specification. There was no separate high priority lane or process.
The Minister will be aware that it has been established that there is in existence an additional 18 VIP lane contracts, bringing the total to 68. Between them, they were awarded £4.9 billion in PPE contracts. Gareth Davies, the head of the National Audit Office, the Comptroller and Auditor General, has said that the Health and Social Care Department was
“open to the risk of fraud.”
What steps are being considered or taken to investigate that and to assure the House that the contracts awarded through the Government VIP lane were not fraudulent?
The Minister will be aware that it has been established that there is in existence an additional 18 VIP lane contracts, bringing the total to 68. Between them, they were awarded £4.9 billion in PPE contracts. Gareth Davies, the head of the National Audit Office, the Comptroller and Auditor General, has said that the Health and Social Care Department was
“open to the risk of fraud.”
What steps are being considered or taken to investigate that and to assure the House that the contracts awarded through the Government VIP lane were not fraudulent?
I can answer the hon. Gentleman. I am delighted to tell him that he has his facts wrong: recent media articles claim that 19 additional suppliers were referred through the HPL, which is totally inaccurate. Having reviewed the records, I can tell him that only one other company was included, so in fact, instead of 50, the total was 51.
To ask the Secretary of State for Health and Social Care, what the proportion of (a) laboratory capacity to process covid-19 PCR tests and (b) contact centre capacity which was paid for has not been used.
To ask the Secretary of State for Health and Social Care, what the proportion of (a) laboratory capacity to process covid-19 PCR tests and (b) contact centre capacity which was paid for has not been used.
We do not set utilisation targets for laboratories as this is dependent on public demand for polymerase chain reaction testing.
The contact centre aligns resources to the forecasted growth or reduction in positive cases across the country. As figures fluctuate daily it is not possible to predict the exact number of agents to meet utilisation targets. However, the performance of the contact centres is monitored. In January 2022, 62% utilisation on the Trace Service and 63% on the general public testing enquires line was reached.
The information requested on paid for laboratory capacity which has not been utilised could only be obtained at disproportionate cost. Between October 2021 and January 2022, the contact centre and 119 service did not use an average of 28% of paid time.
To ask the Secretary of State for Health and Social Care, what the utilisation targets are in respect of (a) laboratory capacity to process covid-19 PCR tests and (b) contact centre capacity; and whether those targets have been reached.
To ask the Secretary of State for Health and Social Care, what the utilisation targets are in respect of (a) laboratory capacity to process covid-19 PCR tests and (b) contact centre capacity; and whether those targets have been reached.
We do not set utilisation targets for laboratories as this is dependent on public demand for polymerase chain reaction testing.
The contact centre aligns resources to the forecasted growth or reduction in positive cases across the country. As figures fluctuate daily it is not possible to predict the exact number of agents to meet utilisation targets. However, the performance of the contact centres is monitored. In January 2022, 62% utilisation on the Trace Service and 63% on the general public testing enquires line was reached.
The information requested on paid for laboratory capacity which has not been utilised could only be obtained at disproportionate cost. Between October 2021 and January 2022, the contact centre and 119 service did not use an average of 28% of paid time.
To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with the Medicines and Healthcare products Regulatory Agency on plans to streamline the approval process of UK-made covid-19 tests.
To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with the Medicines and Healthcare products Regulatory Agency on plans to streamline the approval process of UK-made covid-19 tests.
Approval of COVID-19 tests for private use falls under the Coronavirus Test Devices Approvals regulation (CTDA). The CTDA process is robust, only devices that meet the high regulatory standards are available to the British public. Medicines and Healthcare products Regulatory Agency were heavily involved from the start in setting these high-performance standards.
25% of approved devices are from United Kingdom manufacturers, however, it is important as a fair and neutral regulator of market access that all applicants are treated equally and the Government is working at speed to review applications for devices submitted via this process. We have increased the number of scientific advisors to meet clinical demand and speed up CTDA approvals. Discussions are ongoing about how to further align regulation to ensure it works best for industry and the public.
To ask the Secretary of State for Health and Social Care, what the amount (a) spent in 2020-21 and (b) of projected spend in 2021-2022 is on the purchase of (a) PCR tests, (b) lateral flow tests, (c) PPE and (d) other covid-19 testing equipment.
To ask the Secretary of State for Health and Social Care, what the amount (a) spent in 2020-21 and (b) of projected spend in 2021-2022 is on the purchase of (a) PCR tests, (b) lateral flow tests, (c) PPE and (d) other covid-19 testing equipment.
We are unable to provide the amount spent in the 2020/21 and 2021/22 financial years on the purchases of PCR tests, lateral flow device tests and other COVID-19 testing equipment, as this information is commercially sensitive.
To ask the Secretary of State for Health and Social Care, what further steps he will take to tackle the backlog of applications which have been submitted to the Coronavirus Test Device Approval process.
To ask the Secretary of State for Health and Social Care, what further steps he will take to tackle the backlog of applications which have been submitted to the Coronavirus Test Device Approval process.
Addressing the backlog is a priority, however most applicants did not initially provide evidence of the correct type or standard. We have provided feedback to applicants on what additional information is required to progress their application and allowed the appropriate time to provide it.
We have made improvements to the process that have seen an increased flow of applications to the final stages. These steps include increasing the number of scientific advisors to meet demand, as well as updating the online guidance for applicants on 7 February 2022 to provide greater clarity for acceptance criteria for the range of viral loads within samples. This should enable applications to move through the process more efficiently.
We will continue to work with stakeholders to identify opportunities to streamline the process.
To ask the Secretary of State for Health and Social Care, how much was spent by his Department on (a) laboratory capacity to process PCR tests and (b) contact tracing including contact centres in 2020-2021; and what estimate he has made of the projected spends for those areas in 2021-2022.
To ask the Secretary of State for Health and Social Care, how much was spent by his Department on (a) laboratory capacity to process PCR tests and (b) contact tracing including contact centres in 2020-2021; and what estimate he has made of the projected spends for those areas in 2021-2022.
We are unable to provide the amount spent in the 2020/21 financial year on laboratory capacity for the purposes of processing PCR tests and an estimate of projected spend in that area, as this information is commercially sensitive.
The interim unaudited financial position indicates that expenditure on Trace activities, in the 2020/21 financial period was approximately £911 million. A breakdown of NHS Test and Trace audited expenditure for 2020/2021 will be published once finalised.
As of 31 December 2021, the unaudited projected spend on Trace activities for 2021/22 was £589 million.